Ligand Pharmaceuticals (LGND) Non Operating Investment Income (2017 - 2026)

Ligand Pharmaceuticals (LGND) has 10 years of Non Operating Investment Income data on file, last reported at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Investment Income rose 131.28% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $34.7 million (up 172.05% YoY), and the FY2025 full-year result was $18.4 million, down 75.43% from the prior year.
• Non Operating Investment Income retreated to $3.9 million in Q1 2026, from $22.1 million in the prior quarter.
• In the past five years, Non Operating Investment Income ranged from a high of $110.8 million in Q1 2024 to a low of -$23.9 million in Q4 2024.
• A 5-year average of $10.1 million and a median of $2.4 million in 2024 frame the typical range for Non Operating Investment Income.
• Across the five-year window, Non Operating Investment Income jumped 430.27% in 2022 and slumped 1328.39% in 2023, its largest moves.
• Tracing LGND's Non Operating Investment Income over 5 years: stood at $44.2 million in 2022, then tumbled by 63.78% to $16.0 million in 2023, then tumbled by 249.14% to -$23.9 million in 2024, then jumped by 192.32% to $22.1 million in 2025, then sank by 82.46% to $3.9 million in 2026.
• Business Quant data shows LGND's Non Operating Investment Income at $3.9 million in Q1 2026, $22.1 million in Q4 2025, and $7.8 million in Q3 2025.